Giacobello Scott M. 4

4 · Whitehawk Therapeutics, Inc. · Filed Apr 3, 2026

AI-generated summary of this filing

Updated Apr 3, 2026

Whitehawk (WHWK) CFO Scott Giacobello Exercises Derivative, Receives Award

What Happened

Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics (WHWK), exercised/converted a derivative instrument covering 473,902 shares on 2026-04-01 (transaction code M). The filing shows a corresponding disposition of those 473,902 derivative shares at $0.00 (no cash proceeds reported).
On the same date he was granted/awarded 300,677 restricted stock units (RSUs) (transaction code A) at $0.00. Under the filing footnotes, each RSU represents the contingent right to one share and vests 100% on the one‑year anniversary of the Vesting Commencement Date (April 1, 2025 → vests April 1, 2026), subject to continued service.

Key Details

Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (timely — within the usual 2 business‑day window).
Exercise/conversion: 473,902 shares (code M); corresponding disposition recorded at $0.00 (no cash proceeds shown).
Award: 300,677 RSUs (code A) granted at $0.00; F1/F2 apply — each RSU = 1 share; 100% vest on 4/1/2026 if still a service provider.
Footnote F3 describes a separate option vesting schedule (25% after one year, then monthly over four years starting 4/1/2026) for options in the plan.
Shares owned after the transactions are not disclosed in the provided excerpt.

Context

The filing combines a derivative exercise/conversion and an RSU grant. The $0.00 disposition indicates this was not a cash sale of shares — it appears to be a conversion/settlement or internal reclassification rather than an open‑market sale.
RSU grants are acquisitions that can be interpreted as a form of compensation/retention; they do not necessarily signal personal market conviction.
All explanations above are limited to what the Form 4 and its footnotes disclose; motivations are not stated.

Form 4

Period: 2026-04-01

CHIEF FINANCIAL OFFICER

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-04-01+473,902→ 502,002 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-04-01−473,902→ 0 total
→ Common Stock (473,902 underlying)
Award
Stock Option (right to buy)
[F3]
2026-04-01+300,677→ 300,677 total
Exercise: $3.54Exp: 2036-04-01→ Common Stock (300,677 underlying)

Footnotes (3)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
[F2]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025.
[F3]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.

Signature

/s/ Stephen Rodin, as Attorney-in-Fact|2026-04-03

1 file